% | $
Quotes you view appear here for quick access.

ImmunoGen, Inc. Message Board

mt_cervin 6 posts  |  Last Activity: 13 hours ago Member since: Aug 6, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • The Best of ASCO Program presents the scientific and educational highlights of the ASCO Annual Meeting selected from the year’s notable abstracts. Please see the agenda below for more information.
    Meeting Chair: John Cox, DO, The University of Texas Southwestern

    Friday, 3 June, 08:10-09:00 : 2nd of five abstracts presented during this session is
    "Abstract 500: Pathologic complete response rates after neoadjuvant trastuzumab emtansine (T-DM1) + pertuzumab vs docetaxel + carboplatin + trastuzumab + pertuzumab treatment in patients with HER2-positive early breast cancer (KRISTINE). (Sara A. Hurvitz)"

    Sentiment: Strong Buy

  • mt_cervin mt_cervin 13 hours ago Flag

    From abstract:
    Patients with an increased a-FR expression level had poorer responses to chemotherapy (per a-FR expression level increase: odds ratio (OR): 8.97 (95% confidence interval (CI): 1.40e57.36), p ¼ 0.021). An increased a-FR expression level was an independently poor prognostic factor for disease free interval (DFI) (per a-FR expression level increase: hazard ratio (HR): 2.45 (95% CI: 1.16e5.18), p ¼ 0.02) and had a negative impact on overall survival (OS) of these serous ovarian cancer patients (per a-FR expression level increase: HR: 3.6 (95% CI: 0.93e13.29), p ¼ 0.03) by multivariate analyses. a-FR inhibited cytotoxic drug-induced apoptosis in our in vitro apoptotic assays.

    Sentiment: Strong Buy

  • mt_cervin mt_cervin May 3, 2016 3:56 AM Flag

    KRISTINE likely to disappoint since not listed in Roche's "Curtain Raiser" press release on ASCO as one of its top news

    Sentiment: Strong Buy

  • Senol et al in
    Int J Clin Exp Pathol 2015;8(5):5633-5641

    Endometrioid-type endometrial carcinoma (EEC) developing on the ground of endometrial hyperplasia (EH) is amongst the most commonly observed type of cancer in the world. Folate receptor α (FRα) is a vitamin molecule that has a role in cell proliferation. The fact that FRα, which is known to be needed extremely by the cells of malignancies that proliferate rapidly, is present in limited amounts in normal tissues while it is overexpressed in malignant cells of the same tissues makes folate a candidate for target molecular therapy. In our study, FRα expression in 214 cases, with 95 diagnosed within EEC and 119 with EH, was studied immunohistochemically. FRα expression in EEC was found significantly high compared to EH and normal endometrium (P

    Sentiment: Strong Buy

  • I'm extending herewith a discussion started at referring to Chen et al. 2012, Molecular Oncology (

    Sentiment: Strong Buy

  • Jones et al.,Int. J. Cancer: 123, 1699–1703 (2008)
    Advanced and recurrent endometrial cancers account for the majority of deaths from this disease with limited therapeutic options. High grade, and nonendometrioid histology, pathologically characterize the endometrial tumors associated with adverse outcome and are classified as ‘‘high risk’’. The identification of molecular prognostic factors that might be targeted for therapy among ‘‘high risk’’ endometrial cancers is an active area of investigation. We hypothesize that the FRa, highly expressed in endometrial cancer cells, is a potential target for this disease. Our objectives were to determine if FRa overexpression is associated with adverse prognostic factors and worse outcome. Three hundred and thirty-two endometrial cancer cores were arrayed onto a tissue microarray and stained using a FRa-specific monoclonal antibody. Staining was scored as absent or weak and moderate or strong. Forty-one percent of 310 evaluable cases stained moderate/strong. Moderate/strong FRa staining was significantly associated with other poor prognostic factors including: advanced stage, nonendometrioid histology and high grade. An association was observed between moderate/strong FRa staining and recurrence (p

    Sentiment: Strong Buy

5.56-0.01(-0.18%)May 23 4:00 PMEDT